Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Schroders Capital Global Innovation Trust
London, England, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
As of 2024-2025, 10 out of 12 life science portfolio companies reached clinical stage; several show clinical proof of concept, with device Cequr receiving regulatory approval. The trust is in managed wind-down, aiming to realize portfolio assets and return cash to shareholders.
- Therapeutic areas
- CardiovascularEndocrinologyMetabolic DisordersOtherOncology
- Modalities
- Small moleculeMonoclonal antibodyDeviceDigital health platforms
- Industry
- Investors
02
Partnerships
With portfolio managers (Schroders Capital, Schroder Investment Management Limited)Partnerships with IBT (International Biotechnology Trust)
Beyond the preview
Go deeper on Schroders Capital Global Innovation Trust.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Schroders Capital Global Innovation Trust.